Coloplast's urology business takes growth leap after Covid-19 dive
![Photo: Niels Hougaard/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13420304.ece/ALTERNATES/schema-16_9/doc7i7xtenv03au1vxt5ey.jpg)
While Coloplast's business area Continence Care saw an organic growth of 5 percent in the financial year that just ended, where the Ostomy Care also grew with 6 percent, the medtech company's urology division skyrocketed with an organic growth of 19 percent in the same period, the company's states in its 2020/2021 financial full-year report.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Coloplast expects organic growth of 7 percent next year
For subscribers
Coloplast could win big on Polish reimbursement changes
For subscribers